交易信息汇总资金流向 经财务部门初步测算，预计2025年年度实现归属于母公司所有者的净利润为24,498.80万元至28,798.80万 元，同比上升96.01%至130.41%；扣除非经常性损益的净利润为22,953.60万元至26,953.60万元，同比上 升142.80%至185.11%。本期业绩增长主要因产品线纳入集采后释放增长潜力，推进国际化业务布局， 提升经营管理水平和经营效率。本次业绩预告未经注册会计师审计。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：1月30日主力资金净流出278.01万元，游资资金净流入516.47万元。 来自公司公告汇总：预计2025年净利润同比增长96.01%至130.41%，主要受益于集采释放增长潜 力及国际化业务推进。 1月30日主力资金净流出278.01万元，占总成交额2.59%；游资资金净流入516.47万元，占总成交额 4.81%；散户资金净流出238.46万元，占总成交额2.22%。 公司公告汇总2025年年度业绩预增公告 截至2026年1月30日收盘，春立医 ...

截至2026年1月30日收盘，赛诺医疗(688108)报收于24.33元，上涨0.95%，换手率3.73%，成交量15.59万 手，成交额3.73亿元。 当日关注点 交易信息汇总 资金流向 1月30日主力资金净流出419.74万元，占总成交额1.13%；游资资金净流入1266.56万元，占总成交额 3.4%；散户资金净流出846.82万元，占总成交额2.27%。 业绩披露要点 业绩预告 赛诺医疗发布业绩预告，预计2025年全年扣非后净利润盈利3000万元至3580万元。赛诺医疗发布业绩预 告，预计2025年全年归属净利润盈利4300万元至5000万元。赛诺医疗发布业绩预告，预计2025年全年营 业收入5.19亿元至5.26亿元。 公司公告汇总 赛诺医疗科学技术股份有限公司2025年度业绩预增公告 赛诺医疗预计2025年度营业收入为51,940万元至52,600万元，同比增长13%至15%；归属于上市公司股 东的净利润为4,300万元至5,000万元，同比增长2,767%至3,233%；扣除非经常性损益后的净利润为3,000 万元至3,580万元，实现扭亏为盈。业绩增长主要得益于冠脉介入和神经介入产品销量增长、 ...

资金流向 1月30日主力资金净流出471.28万元；游资资金净流入468.39万元；散户资金净流入2.89万元。 业绩披露要点 业绩预告 蓝帆医疗发布业绩预告，预计2025年全年扣非后净利润亏损7.8亿元至9.8亿元。蓝帆医疗发布业绩预 告，预计2025年全年每股收益亏损0.65元至0.85元。蓝帆医疗发布业绩预告，预计2025年全年归属净利 润亏损6.5亿元至8.5亿元。 截至2026年1月30日收盘，蓝帆医疗(002382)报收于5.92元，上涨0.51%，换手率1.49%，成交量14.87万 手，成交额8883.0万元。 当日关注点 交易信息汇总 2025年年度业绩预告 蓝帆医疗预计2025年度归属于上市公司股东的净利润亏损65,000.00万元至85,000.00万元，较上年同期亏 损扩大。主要原因为健康防护事业部受国际贸易形势影响订单波动、销售价格承压，且发生跨境关联交 易特别纳税调整补税及固定资产减值损失；心脑血管事业部因参股公司苏州同心估值变动确认公允价值 变动损失约1.2亿元；公司总部计提金融负债相关财务费用1亿元。不考虑非经营性事项，心脑血管事业 部经营业绩实现扭亏并贡献利润。本次业绩预告未 ...

截至2026年1月30日收盘，振德医疗(603301)报收于68.77元，上涨2.87%，换手率0.77%，成交量2.04万 手，成交额1.39亿元。 当日关注点 交易信息汇总 资金流向 1月30日主力资金净流入832.09万元，占总成交额5.99%；游资资金净流出991.53万元，占总成交额 7.13%；散户资金净流入159.43万元，占总成交额1.15%。 公司公告汇总 振德医疗2026年第二次临时股东会会议材料 振德医疗拟对第二期员工持股计划（草案）及其管理办法进行修订，明确未解锁股份由公司回购注销， 并修订持有人权益处置方式。同时，公司拟回购第二期员工持股计划未解锁的1,829,868股股份，回购价 格为22.17元/股。此外，拟将已回购但未使用的129,442股及上述拟回购股份合计1,959,310股用途变更为 注销，公司总股本将由265,835,535股减少至263,876,225股，并相应修改公司章程，办理工商变更登记。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：1月30日主力资金净流入832. ...

■张敏 2025年度业绩预告正密集披露，医药板块上市公司的经营成绩单逐渐浮出水面，并呈现出鲜明的"冰火 两重天"现象：一端是部分依赖传统模式的企业，受市场竞争加剧等因素影响，增长明显承压；另一端 是一批在创新与"出海"方面取得突破的企业，展现出强劲的增长动能与发展韧性。这一分化在生物制 品、医疗器械、化学制药等多个细分板块均有所体现。 笔者认为，这种业绩分化并非短期市场波动所致，而是医药行业增长引擎加速切换的必然结果：行业正 从过去依赖国内市场红利与仿制跟随模式，加速转向以全球化发展与创新驱动为核心的模式。面向未 来，行业必须深刻意识到，"出海"与"创新"已成为必答题，从业者必须加快转型步伐。 面向未来，能否答好"创新"与"出海"这两道核心考题，关乎每一家企业乃至整个中国医药产业在未来全 球生物医药版图上的坐标。动能转换的进程已然加速，唯有主动拥抱变革、锻造核心能力者，方能赢得 下一个黄金发展期的入场券。 一是创新药的"授权出海"与"自主出海"双轮驱动。去年，我国创新药海外授权交易总额突破1300亿美 元。今年以来，多家生物科技公司与大型药企将更多具有国际竞争力的原创产品，通过授权合作或自主 推进国际多中心临 ...

Group 1 - In January, private equity firms actively participated in offline subscription for new stocks, with 159 firms involved in 5 stocks, acquiring a total of 15.76 million shares worth approximately 338 million yuan [1] - The semiconductor equipment company Hengyun Chang attracted the most attention from private equity, with a total allocation amount of about 114 million yuan and 1.236 million shares acquired [1] - Other notable companies included Zhenstone Co., a wind power materials manufacturer, with an allocation of approximately 86.16 million yuan and 7.707 million shares, and Beixin Life, a medical device company, with about 66.47 million yuan and 3.794 million shares allocated [1] Group 2 - Among the participating private equity firms, over 80% of the 47 firms with allocations of at least 1 million yuan managed over 10 billion yuan, including 27 quantitative private equity firms [1] - The top participant in terms of allocation was Ningbo Huansheng Quantitative Investment Management, with an allocation of approximately 32.68 million yuan and 1.4026 million shares [2] - Other significant participants included Jiukun Investment with about 32.22 million yuan and 1.3153 million shares, and Shanghai Yanfu Investment Management with approximately 25.64 million yuan [2] Group 3 - The concentration of large quantitative private equity firms in offline subscriptions is attributed to their disciplined and systematic investment strategies, which align well with the requirements of new stock subscriptions [3] - The stable returns from new stock subscriptions provide effective support for fund net values, making them attractive for quantitative strategies [3] - Subjective strategy private equity firms also showed active participation, with firms like Shanghai Yingshui Investment and Shanghai Ningquan Asset Management acquiring amounts ranging from 3.96 million to 5.59 million yuan [3]

Core Viewpoint - The company DaAn Gene announced an expected net profit attributable to shareholders for 2025 to be between -865 million yuan and -607 million yuan, compared to -925 million yuan in the same period last year, indicating a slight improvement in losses [1][4]. Financial Summary - The projected net profit attributable to shareholders for 2025 is between -865 million yuan and -607 million yuan, while the previous year's figure was -925 million yuan [2][5]. - The net profit after deducting non-recurring gains and losses is expected to be between -938 million yuan and -658 million yuan, compared to -823 million yuan in the same period last year [2][5]. - Basic earnings per share are projected to be between -0.62 yuan and -0.43 yuan, compared to -0.66 yuan in the previous year [2][5]. - For the first three quarters of 2025, the company reported revenue of 504 million yuan and a net profit attributable to shareholders of -142 million yuan, with a significant decline expected in the fourth quarter [2][5]. Reasons for Performance Changes - The decrease in operating revenue is attributed to market demand, the implementation of centralized procurement policies, and an increase in the VAT rate on self-produced reagent products to 13%. Despite efforts to enhance operational efficiency, fixed costs have led to a negative impact on gross profit, resulting in operational losses for the year [3][6]. - The performance of joint ventures improved compared to the previous year, leading to an increase in investment income recognized by the company, which positively affected the net profit attributable to shareholders [3][6]. - The company has strengthened the collection of historical accounts receivable, resulting in a decrease in the provision for credit impairment losses compared to the previous year. However, the company also conducted a comprehensive review of various assets and recognized impairment losses on assets showing signs of impairment, which increased compared to the previous year [3][6]. - The fair value of other non-current financial assets increased, contributing to a rise in net profit attributable to shareholders, with this non-recurring gain before tax increasing by approximately 180 million yuan compared to the previous year [3][6].

Group 1: Company Overview - Yisiwei's IPO price is set at 7.67 CNY per share, focusing on machine vision equipment for the automotive manufacturing sector, providing solutions across various manufacturing processes [1] - The company is projected to achieve a market share of 13.7% in China's automotive manufacturing machine vision market and 22.5% in the overall automotive manufacturing sector by 2024, leading the industry [1] - Yisiwei has developed over ten products, covering six major manufacturing processes, establishing a comprehensive product range and application advantage, serving most domestic automotive manufacturers [1] Group 2: Business Growth and Financial Performance - From 2022 to 2024, Yisiwei's revenue is expected to grow from 22.3 million CNY to 39.2 million CNY, with a compound annual growth rate (CAGR) of 32.59%, while net profit is projected to increase from 5.39 million CNY to 84.43 million CNY, with a CAGR of 295.66% [2] - Aide Technology's IPO price is set at 55.95 CNY per share, focusing on orthopedic medical devices, including spinal, trauma, and sports medicine products [2] - The total fundraising amount for Aide Technology is 197.02 million CNY, aimed at expanding orthopedic consumables production, building a research center, and developing a marketing network [2] Group 3: Market Trends - The market size for orthopedic implant medical devices in China is expected to grow from 19.3 billion CNY in 2016 to 24.6 billion CNY by 2024, with a CAGR of 3.08%, despite a recent market contraction due to procurement policies [2] - Specific segments, such as the sports medicine market, continue to show growth despite overall market challenges [2]

本次活动由四川省药品监督管理局、成都东部新区管委会联合主办，以"临床驱动，生态赋能，共筑医 疗器械创新转化新高地"为主题，汇聚近200位政、医、学、研、产领域嘉宾，共同搭建高效对接桥梁， 推动一批具有临床价值的创新医疗（002173）器械项目加速落地，标志着川渝地区在构建"临床需求— 研发创新—产业落地—政策支持—金融助力"五位一体的医疗器械创新生态体系上迈出了坚实一步。 活动现场 图片来源：成都东部新区提供 1月31日，医疗器械领先用户社区应用示范暨"春雨行动"临床研究成果转化对接会在成都东部新区未来 医学城举行。 作为成都东部新区生物医药产业发展高地，成都未来医学城以临床医疗应用为创新原点，构建起"医教 研产"一体化创新发展体系，致力于打造一座未来医学创新与探索前沿、医教研产融合与转化典范的生 命健康之城。此次活动既是临床创新成果的集中亮相，也是成都未来医学城"医教研产"协同发展的生动 展现。作为川渝首个"医疗器械领先用户社区应用示范点"，成都未来医学城锚定"西部医疗器械创新高 地"定位，以"立园满园"行动为引领，正持续完善创新转化保障体系，全力破解医疗器械临床研究成果 转化中"不愿转、不敢转、不会转"的 ...

Trading Activity - The average daily trading amount on the North Exchange increased by 8.83% to 28.738 billion yuan[7] - The weekly turnover rate for the North Exchange was 27.94%[7] - The North Exchange's trading amount accounted for 0.94% of the total market, remaining stable compared to the previous week[11] Index Performance - The North 50 Index declined by 3.59% during the week[16] - Other major indices also experienced declines, with the ChiNext Index down by 0.91% and the Shanghai Composite Index up by 0.10%[16] Sector Analysis - Most sectors on the North Exchange had negative median returns, with the petroleum and petrochemical sector leading with a median increase of 33.99%[21] - The power equipment sector had the largest median decline at -8.07%[21] - The computer industry had the highest median P/E ratio at 139.33 times, indicating high valuation compared to other sectors[21] New Listings - One new stock was offered and two new stocks were listed on the North Exchange during the week[44] - The first-day average price increase for the newly listed stocks was 105.63% for Agricultural University Technology and 186.93% for Meidel[44] New Third Board Trading - The trading scale of the New Third Board decreased, with the innovative tier's trading amount down by 12.08% to 0.965 billion yuan, while the basic tier increased by 22.05% to 0.372 billion yuan[36]